Company information Dr. Reddy's Denmark ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Regnskabstal2024–2025
| 2023/24 | 2025 | |
|---|---|---|
| Balance — aktiver | ||
| Likvide beholdninger | — | 6.802.951 |
| Omsætningsaktiver i alt | — | 183.175.257 |
| Anlægsaktiver i alt | — | 2.915.058 |
| Aktiver i alt | — | 186.090.315 |
| Balance — passiver | ||
| Kortfristede gældsforpligtelser | — | 175.386.533 |
| Langfristede gældsforpligtelser | — | 1.663.696 |
| Gældsforpligtelser i alt | — | 177.050.229 |
| Selskabskapital | — | 41.000 |
| Overført resultat | — | 7.040.086 |
| Årets resultat | — | 7.040.086 |
| Egenkapital i alt | 41.000 | 9.040.086 |
| Resultatopgørelse | ||
| Omsætning | — | 226.616.368 |
| Bruttofortjeneste | — | 56.434.002 |
| Resultat af primær drift | — | 11.813.535 |
| EBITDA | — | 12.195.962 |
| Resultat før skat | — | 9.315.933 |
| Årets resultat | — | 7.040.086 |
| Personaleomkostninger | — | 14.536.405 |
| Af- og nedskrivninger | — | 382.427 |
| Andre nøgletal | ||
| Ansatte | — | 9 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025The Company commenced its activities on 4 October 2024. The Company’s main activity is the sale of pharmaceutical preparations. During the period, the Company has established and carried out its commercial operations in line with its purpose.
Development in activities and finances The Company was incorporated on 4 October 2024 and this annual report covers its first financial reporting period. The Company's activities comprise the marketing and sale of Nicotinell nicotine replacement therapy products in the Nordics. During the period, the Company established its operational and commercial platform following the Dr. Reddy's Group's acquisition of the Nicotinell business in Northern Europe, and commenced full commercial operations in the Nordic region. Revenue for the period amounted to TDKK 226,616, reflecting the successful establishment of the Company's commercial operations and market presence. The period was characterised by investments in personnel, commercial capabilities and supporting infrastructure required to build the business and support future growth. The Company realised a profit for the period of TDKK 7,040. Equity amounted to TDKK 9,040 as at 31 December 2025. Management considers the development in activities and financial performance during the Company's first reporting period to be satisfactory. The result demonstrates the successful establishment of the business and provides a solid foundation for the continued development of the Nicotinell operations in the Nordics.
Uddrag af ledelsesberetningen i den seneste årsrapport.